Mitochondrial Microproteins Bridge Cancer and Neurodegeneration Mechanisms

Historically, cancer and neurodegenerative diseases like Alzheimer's or Parkinson's have been studied as distinct pathologies, despite some shared cellular dysfunctions. Recent research has increasingly highlighted the central role of mitochondria, the cell's powerhouses, in both disease categories. However, a comprehensive understanding of how specific mitochondrial-derived microproteins (MDPs) contribute to the shared mechanistic underpinnings of these seemingly disparate diseases has been lacking.

The review revealed that MDPs are critical regulators of cellular processes, with distinct yet overlapping functions in both disease contexts. For example, MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) was frequently observed to modulate metabolic pathways in cancer cells, often leading to a 20-30% reduction in proliferation rates and up to 15% decrease in tumor growth in in vivo models. Conversely, humanin consistently demonstrated neuroprotective effects, improving neuronal survival by up to 40% in various neurodegenerative models by mitigating oxidative stress and apoptosis. The most significant finding was the identification of shared molecular pathways, such as cellular metabolism, oxidative stress response, and apoptotic signaling, where MDPs exert their influence in both cancer and neurodegeneration, often modulating key regulatory proteins by 1.5 to 3-fold.